Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.30 |
| ▸ | AHCY | P23526 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14212364 | 0.91 | ADORA3 (0.33) | ADORA3ADORA1TSHRLMNATHRB | |
| SCHEMBL19220862 | 0.91 | ADORA3 (0.33) | ADORA3ADORA1TSHRLMNATHRB | |
| SCHEMBL19220863 | 0.91 | ADORA3 (0.33) | ADORA3ADORA1TSHRLMNATHRB | |
| SCHEMBL19276856 | 0.86 | ADORA3 (0.42) | ADORA3LGALS8ADORA1TSHRLMNA | |
| SCHEMBL19276862 | 0.86 | ADORA3 (0.42) | ADORA3LGALS8ADORA1TSHRLMNA | |
| SCHEMBL18971396 | 0.79 | ADORA3 (0.38) | ADORA3LGALS8ADORA1TSHRLMNA | |
| SCHEMBL18971393 | 0.79 | ADORA3 (0.38) | ADORA3LGALS8ADORA1TSHRLMNA | |
| SCHEMBL23710807 | 0.77 | CA12 (0.33) | — | |
| SCHEMBL22292120 | 0.75 | SMN1; SMN2 (0.33) | ADORA3TSHRLMNATHRBBLM | |
| SCHEMBL18218366 | 0.74 | CAPN1 (0.31) | TSHRLMNAHSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130084-A1 | MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130084-A1 | MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY | ALG1, CD44, CD47 | ADORA3 3521/4885LGALS8 280/4885ADORA1 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.